Novara Biotech reports quarterly revenue above the internal plan
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
Novara Biotech
Healthcare · Biotechnology
Updated UTC
US$ 410,77
+5,46+1,35%
After hoursUS$ 412,82+0,50%
| Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | 31,67 mld. | 37,26 mld. | 41,96 mld. | 48,31 mld. | 53,67 mld. |
| Gross profit | 18,76 mld. | 21,53 mld. | 23,9 mld. | 26,46 mld. | 32,34 mld. |
| Operating income | 6,26 mld. | 7,62 mld. | 7,85 mld. | 9,58 mld. | 11,72 mld. |
| Net income | 4,88 mld. | 5,63 mld. | 6,17 mld. | 5,78 mld. | 7,65 mld. |
Clinical-stage developer of oral therapies for autoimmune and metabolic disorders.
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
The company approved a multi-year capital program intended to shorten lead times for its largest customers.
Sector Desk
A sell-side desk kept a neutral rating while noting that near-term estimates already reflect steady execution.
Sector Desk
The board named an internal candidate with prior treasury and investor-relations experience to the role.
Sector Desk
The authorization covers a modest slice of the float and will be funded from operating cash flow.
Terminal Brief